Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Targovax ASA ( (GB:0RIS) ) just unveiled an update.
Circio Holding ASA has announced a share capital increase following the conversion of convertible bonds by Atlas Special Opportunities, LLC, which has been registered with the Norwegian Register of Business Enterprises. This development reflects the company’s ongoing efforts to strengthen its financial position and support its innovative biotechnology endeavors, including its circVec platform and TG01 cancer vaccine trials, potentially impacting its market positioning and stakeholder interests.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing advanced RNA technology for nucleic acid medicine. They have created a unique circular RNA vector expression platform, known as circVec, which enhances protein expression significantly compared to traditional mRNA systems. This platform is applicable in various therapeutic areas, including genetic medicine, cell therapy, and chronic disease. Additionally, Circio is working on a pan-RAS cancer vaccine, TG01, targeting KRAS mutations, with ongoing clinical trials in the USA and Norway.
Average Trading Volume: 1,153,905
Current Market Cap: NOK62.66M
For detailed information about 0RIS stock, go to TipRanks’ Stock Analysis page.